Apellis Pharmaceuticals, Inc. (APLS)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$41.030.00%
Close 2026-05-14 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · APLS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
APLS — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-05-14
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 13, 2026, the Company (i) notified The Nasdaq Stock Market (“Nasdaq”) of the anticipated consummation of the Merger and (ii) requested that Nasdaq (x) suspend trading of the Shares, effective at 8:00 p.m., Eastern Time, on May 13, 2026, and, following the Effective Time, (y) file with the U.S. Securities and Exchange Commission (the “SEC”) a Form 25, Notification of Removal from Listing…
Why it matters: Q2 results will show how the merger affects revenue and other financial metrics.
Watch forQ2 revenue shows significant growth compared to Q1 2026.
Also watch forQ2 revenue declines or shows minimal growth compared to Q1 2026.
Why it matters: The repurchase outcome will show how investors view the company's future.
Watch forMany noteholders choose to repurchase their notes on June 30, 2026.
Also watch forLow participation in the repurchase shows a lack of trust in the company's plans.
Why it matters: The acquisition will change Apellis' structure and strategy. This affects future growth.
Supportive ifAn official announcement confirms the acquisition is done. Trading will start again.
Worry ifThere are more delays or problems with the acquisition process.
Why it matters: A successful buyback can raise share value. It also shows management's trust in the company.
Supportive ifThe company says it has finished a big part of the buyback program.
Worry ifThe company delays or cancels the buyback program.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$98 on $10,000 · ±1.0% | How much price usually moves either way. |
| Bad day | $401 loss on $10,000 · 4.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,353 loss on $10,000 · 43.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Changes in leadership can affect company plans and actions. It shows if the new team is stable.
Worry ifNo resignations or changes in leaders show that things are stable.
Less concerning ifMore leaders leaving or problems in leadership after the merger.
Why it matters: Changes in leaders can change company plans and results. Watching this can show future paths.
Watch forNew leaders are chosen that match the goals of the merged company.
Also watch forMore leaders leaving or problems in leadership can hurt operations.
Why it matters: The acquisition may change how Apellis operates. Investors will watch for its impact on finances.
Supportive ifFinancials show a big rise in revenue or net income after the acquisition.
Worry ifFinancials stay the same or drop, showing no good effect from the acquisition.
Why it matters: The buyback can raise share value. It shows management's confidence and spending priorities.
Supportive ifThe buyback program is causing a clear rise in share price or investor interest.
Worry ifThe buyback fails to support share price or is met with negative investor sentiment.
Why it matters: If stockholders accept the tender offer, it shows they trust the merger.
Supportive ifMost stockholders must tender their shares by the deadline.
Worry ifA low acceptance rate of the tender offer shows stockholder doubt.
Why it matters: Completing the acquisition will impact Apellis' future work and money situation. This is an important step for the company.
Supportive ifThe acquisition is complete. All regulatory approvals are in place by the end of Q3 2026.
Worry ifThe acquisition has delays or regulatory issues. This pushes the completion past Q3 2026.
Why it matters: The buyback program shows Apellis wants to give value back to shareholders after the merger.
Supportive ifThey announce the buyback with details on how many shares and when.
Worry ifNo news or delays in the buyback could mean money problems.
Why it matters: The acquisition will affect Apellis's future operations and finances. It shows a good match with Biogen.
Supportive ifAn official announcement will confirm the merger is done. It will also share plans for integration.
Worry ifAn announcement will detail delays or problems in the merger process.
Why it matters: Updates on CVR payments show how well the merger is doing with its goals.
Supportive ifManagement says that CVR milestones have been met.
Worry ifManagement states that CVR milestones are not met or delayed.
Why it matters: A successful buyback can raise earnings per share. It shows management believes in the company.
Supportive ifManagement says there is a big drop in outstanding shares because of the buyback.
Worry ifThe buyback program fails to reduce share count significantly or is halted.
Why it matters: If the tender offer works, it will change shareholder value and company plans.
Watch forMost shareholders accept the tender offer, which leads to the merger.
Also watch forLow acceptance of the tender offer shows that shareholders are not on board.